Angiotensin II formation by an alternative pathway during exercise in humans
- PMID: 7836734
Angiotensin II formation by an alternative pathway during exercise in humans
Abstract
Objective: We postulated a 'kinin-tensin system' in which angiotensin II (Ang II) is cleaved by one or more serine protease independent of renin or angiotensin converting enzyme (ACE). The aim was to determine whether this alternative Ang II-forming pathway by serine proteases participates in the rise in plasma levels of Ang II during exercise in humans.
Design and methods: The study consisted of two double-blind crossover experiments. in experiment 1 six healthy volunteers who had been taking either placebo (group P) or the ACE inhibitor captopril (150 mg/day for 3 days; group C) performed a cycle ergometer graded exercise test at four different exercise intensities: stage 1, half of the intensity at the blood lactate threshold (WLT); stage 2, the intensity at WLT; stage 3, the intensity at 4 mmol/l blood lactate; and stage 4, an intensity between stage 3 and maximum intensity. In experiment 2 the same volunteers took captopril (150 mg/day for 3 days) and performed exercise at an intensity corresponding to 90% of the 4 mmol/l blood lactate intensity for 30 min during intravenous drip injection of a serine protease inhibitor, nafamostat [NAF; 0.2 mg/kg per h; NAF(+) group] or saline [NAF(-) group].
Results: In experiment 1 plasma Ang II levels increased from at rest to after exercise in both groups P and C. Although there was a significant treatment effect, captopril did not significantly alter the exercise-induced changes in Ang II level. In experiment 2 the increase in Ang II level after 30 min exercise in the NAF(+) group was significantly lower than in the NAF(-) group.
Conclusions: These results suggest the presence of an alternative Ang II-forming pathway independent of ACE, and that one or more NAF-sensitive serine protease is responsible, at least partly, for generating Ang II during exercise.
Similar articles
-
Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.Circulation. 1995 Aug 15;92(4):825-34. doi: 10.1161/01.cir.92.4.825. Circulation. 1995. PMID: 7641363 Clinical Trial.
-
Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women.Am J Hypertens. 2006 Jul;19(7):744-9. doi: 10.1016/j.amjhyper.2005.10.006. Am J Hypertens. 2006. PMID: 16814131 Clinical Trial.
-
Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.J Pharmacol Exp Ther. 1998 Nov;287(2):567-77. J Pharmacol Exp Ther. 1998. PMID: 9808682
-
Angiotensin II exerts positive feedback on the intrarenal renin-angiotensin system by an angiotensin converting enzyme-dependent mechanism.J Surg Res. 2005 Dec;129(2):272-7. doi: 10.1016/j.jss.2005.04.044. Epub 2005 Jun 29. J Surg Res. 2005. PMID: 15992826
-
Should the use of short acting angiotensin-converting enzyme inhibitors be abandoned?J Renin Angiotensin Aldosterone Syst. 2000 Dec;1(4):365-8. doi: 10.3317/jraas.2000.068. J Renin Angiotensin Aldosterone Syst. 2000. PMID: 11967825 Clinical Trial.
Cited by
-
Inhibition of angiotensin converting enzyme cannot prevent increases in angiotensin II production in coronary circulation.Heart. 2000 May;83(5):574-6. doi: 10.1136/heart.83.5.574. Heart. 2000. PMID: 10768912 Free PMC article. Clinical Trial.
-
The serum angiotensin-converting enzyme and angiotensin II response to altered posture and acute exercise, and the influence of ACE genotype.Eur J Appl Physiol. 2004 Mar;91(2-3):342-8. doi: 10.1007/s00421-003-0993-1. Epub 2003 Nov 1. Eur J Appl Physiol. 2004. PMID: 14595564 Clinical Trial.
-
Serum activity of Angiotensin converting enzyme and blood pressure response to acute dynamic exercise.Bosn J Basic Med Sci. 2004 Oct;4(4):32-6. doi: 10.17305/bjbms.2004.3357. Bosn J Basic Med Sci. 2004. PMID: 15628993 Free PMC article.
-
Intracrine angiotensin II functions originate from noncanonical pathways in the human heart.Am J Physiol Heart Circ Physiol. 2016 Aug 1;311(2):H404-14. doi: 10.1152/ajpheart.00219.2016. Epub 2016 May 27. Am J Physiol Heart Circ Physiol. 2016. PMID: 27233763 Free PMC article. Review.
-
Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial.Cardiovasc Drugs Ther. 1995 Oct;9(5):693-700. doi: 10.1007/BF00878552. Cardiovasc Drugs Ther. 1995. PMID: 8573552 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous